• Korsana Biosciences completed its merger with Cyclerion Therapeutics, creating a combined company renamed Korsana Biosciences.
• Shares are set to begin trading on Nasdaq on Sept. 9 under ticker KRSA.
• A $380 million private placement closed immediately before the merger, lifting expected post-transaction cash to about $475 million.
• Cyclerion effected a 1-for-7 reverse stock split ahead of the deal; about 55,100,000 shares and equivalents are outstanding post-close.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cyclerion Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-389318), on September 11, 2026, and is solely responsible for the information contained therein.